These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease. Barnum SR Mol Med; 1999 Sep; 5(9):569-82. PubMed ID: 10551898 [No Abstract] [Full Text] [Related]
24. Alternative complement activity in the egg cytosol of amphioxus Branchiostoma belcheri: evidence for the defense role of maternal complement components. Liang Y; Zhang S; Wang Z PLoS One; 2009; 4(1):e4234. PubMed ID: 19156196 [TBL] [Abstract][Full Text] [Related]
25. Nephritic factor, C3 splitting activity, C3 and factor B breakdown products in glomerular diseases. De Vecchi A; Montagnino G; Scalia P; Tarantino A Ric Clin Lab; 1980; 10(1):93-7. PubMed ID: 6781054 [No Abstract] [Full Text] [Related]
26. Complement and Bacterial Infections: From Molecular Mechanisms to Therapeutic Applications. Heesterbeek DAC; Angelier ML; Harrison RA; Rooijakkers SHM J Innate Immun; 2018; 10(5-6):455-464. PubMed ID: 30149378 [TBL] [Abstract][Full Text] [Related]
27. Inhibitors of the complement system currently in development for cardiovascular disease. Pugsley MK; Abramova M; Cole T; Yang X; Ammons WS Cardiovasc Toxicol; 2003; 3(1):43-70. PubMed ID: 12668890 [TBL] [Abstract][Full Text] [Related]
28. [Role of membrane molecules in complement system]. Okada N Rinsho Byori; 1991 Sep; Suppl 91():129-39. PubMed ID: 1721938 [No Abstract] [Full Text] [Related]
31. Inhibitory effect of FUT-175 on complement activation and its application for glomerulonephritis with hypocomplementemia. Fujita Y; Inoue I; Inagi R; Miyata T; Shinzato T; Sugiyama S; Miyama A; Maeda K Nihon Jinzo Gakkai Shi; 1993 Apr; 35(4):393-7. PubMed ID: 8341019 [TBL] [Abstract][Full Text] [Related]
32. Pharmacological manipulation of the complement system in human diseases. Asghar SS Front Biosci; 1996 Mar; 1():e15-25. PubMed ID: 9159241 [TBL] [Abstract][Full Text] [Related]
35. Opsonization of encapsulated Staphylococcus aureus: the role of specific antibody and complement. Verbrugh HA; Peterson PK; Nguyen BY; Sisson SP; Kim Y J Immunol; 1982 Oct; 129(4):1681-7. PubMed ID: 7108223 [TBL] [Abstract][Full Text] [Related]
36. Learnings from over 25 years of PNH experience: the era of targeted complement inhibition. Heitlinger E Blood Rev; 2013 Dec; 27 Suppl 1():S1-6. PubMed ID: 24331206 [TBL] [Abstract][Full Text] [Related]
37. Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones. Chen S; Caragine T; Cheung NK; Tomlinson S Am J Pathol; 2000 Mar; 156(3):1085-91. PubMed ID: 10702424 [TBL] [Abstract][Full Text] [Related]
38. CRP, a major culprit in complement-mediated tissue damage in acute myocardial infarction? Nijmeijer R; Lagrand WK; Visser CA; Meijer CJ; Niessen HW; Hack CE Int Immunopharmacol; 2001 Mar; 1(3):403-14. PubMed ID: 11367525 [No Abstract] [Full Text] [Related]